Teverelix Evaluated in Advanced Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer

Phase 2

Antev Ltd.

Antarelix